A new Baltimore-based life sciences accelerator aims to boost the commercialization of medical technologies emerging from universities and research institutions.
Blackbird Laboratories will identify promising therapeutics and other health-related innovations developed at its partner institutions, which include Johns Hopkins University, the University of Maryland-Baltimore, and the Lieber Institute for Brain Development.
The accelerator will provide funding, program management, and strategic scientific and business input from its team of life science professionals, with the goal of bridging the gap between innovative academic research and industry.
The accelerator is backed by a $100 million founding grant from the Stephen and Renee Bisciotti Foundation, a charitable organization founded by Baltimore Ravens owner Stephen Bisciotti.
“We are thrilled to launch Blackbird Labs, a next-generation life sciences accelerator with a vision to develop new technologies and therapies emerging from premier research institutions here in Baltimore and across the country,” says Matt Tremblay, CEO of Blackbird Labs. “We look forward to utilizing our collective expertise in academic translation, company creation, and drug development and leveraging our academic partnerships to lay the groundwork for the biotech companies of the future.”
Sources: Cision and The Daily Record
